Clinical Trial Detail

NCT ID NCT04147819
Title A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bayer
Indications

gastroesophageal cancer

stomach cancer

carcinoma

Her2-receptor positive breast cancer

Therapies

BAY2701439

Age Groups: senior adult

Additional content available in CKB BOOST